Low-dose low-molecular-weight heparin (enoxaparin) is beneficial in lichen planus: a preliminary report

• Published in: Journal of the American Academy of Dermatology Vol. 38; no. 4; pp. 564 - 568
• Main Authors: Hodak, Emmilia, Yosipovitch, Gil, David, Michael, Ingber, Arieh, Chorev, Liran, Lider, Ofer, Cahalon, Leora, Cohen, Irun R.
• Format: Journal Article
• Language: English
• Published: New York, NY Mosby, Inc 01.04.1998; Elsevier
• Subjects: Adult; Aged; Biological and medical sciences; Biopsy; Dermatology; Enoxaparin - administration & dosage; Enoxaparin - therapeutic use; Female; Follow-Up Studies; Humans; Lichen Planus - drug therapy; Lichen Planus - pathology; Lichen Planus, Oral - drug therapy; Lichen Planus, Oral - pathology; Male; Medical sciences; Middle Aged; Pharmacology. Drug treatments; Psoriasis. Parapsoriasis. Lichen; Skin - pathology; Skin, nail, hair, dermoskeleton; Time Factors; Treatment Outcome; Human; Low molecular weight heparin; Skin disease; Chemotherapy; Treatment; Lichen planus
• ISSN: 0190-9622; 1097-6787
• DOI: 10.1016/S0190-9622(98)70118-5

Background: Low-dose heparin devoid of anticoagulant activity inhibits T-lymphocyte heparanase activity, which is crucial in T-cell migration to target tissues. Objective: The purpose of this study was to assess the efficacy of low-dose enoxaparin (Clexane), a low-molecular-weight heparin, as monotherapy in lichen planus. Methods: Included in the study were 10 patients with widespread histopathologically proven lichen planus (LP) associated with intense pruritus of several months’ duration. Patients were given 3 mg enoxaparin, subcutaneously once weekly; three patients received four injections, and seven patients received six injections. Results: In nine patients the itch disappeared within 2 weeks. Within 4 to 10 weeks in eight of these patients, there was complete regression of the eruption with residual postinflammatory hyperpigmentation; in one patient, there was marked improvement. In one patient, no effect was observed. Of the four patients who also had oral LP, only one showed improvement. No side effects were observed in any of the patients. Conclusion: These findings indicate that enoxaparin may be a simple, effective treatment for cutaneous LP. (J Am Acad Dermatol 1998;38:564-8.)